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Summary: As is apparent in many
fields of science and medicine, the
new biology, and particularly new
high-throughput genetic sequenc-
ing and transcriptomic and epige-
netic technologies, are radically
altering our understanding and
views of science. In this article, we
make the case that while mostly
ignored thus far in the vaccine field,
these changes will revolutionize
vaccinology from development to
manufacture to administration.
Such advances will address a cur-
rent major barrier in vaccinology—
that of empiric vaccine discovery
and development, and the subse-
quent low yield of viable vaccine
candidates, particularly for hyper-
variable viruses. While our labora-
tory’s data and thinking (and hence
also for this paper) has been
directed toward viruses and viral
vaccines, generalization to other
pathogens and disease entities
(i.e., anti-cancer vaccines) may be
appropriate.
Introduction
The goal in vaccinology is to discover,
develop, and deploy highly immunogenic
and safe vaccines that protect against
infectious and non-infectious (i.e., cancers)
diseases in essentially 100% of the popu-
lation. While admirable, such a goal, to
date, fails because of both pathogen and
host variability. For hyper-variable viral
pathogens like HIV, HCV, rhinovirus,
and others, we have been unable to
discover and develop highly immunogenic
and protective vaccine candidates. This is
true too for other highly complex patho-
gens such as bacteria (i.e., tuberculosis)
and parasites (i.e., malaria). Host variabil-
ity is evident in the multiplicity of immune
response genes that encode .10
12 prod-
ucts necessary for generating immune
responses (i.e., antibodies, T cell receptors
[TCRs], etc.), and the estimated diversity
of human leukocyte antigen (HLA) haplo-
types (estimated at .10
13), allowing hu-
mans an almost limitless immune response
capability [1].
Thus, both pathogen and host variability
barriers make it difficult to induce protec-
tive immune responses to vaccine antigens
in 100% of the population—at least for
most of the pathogens of interest for
vaccine public health needs such as HIV,
HBV, HCV, measles, influenza, and
others.
Current Vaccine Development
We propose that an additional ap-
proach to this dilemma resides in changing
the paradigm and conceptual framework
through which we develop new vaccines.
For example, from the 1700s through the
late 1990s, vaccine development was
primarily characterized by an empiric
‘‘isolate – inactivate/attenuate – inject’’
approach. While successful in developing
most of the vaccines we use today, it fails
in the face of hyper-variable and highly
complex pathogens and is an approach
now limited by a lack of innovation, a
predominant single mode of administra-
tion (injection), and a lack of directed
adjuvants to overcome poor immunoge-
nicity of the identified antigen. From a
policy viewpoint, today’s vaccines are
administered to everyone at the same dose
(‘‘one dose fits all’’) as a public health
approach that assumes that everybody is at
risk for every pathogen with equally
devastating risks of complications. Too,
our past and current approach to vaccines
is prophylactic only (we have no thera-
peutic vaccines), is overwhelmingly aimed
at childhood diseases (ignoring demo-
graphic trends of aging populations in
every developed economy), and at least in
the US, is exclusively a private sector, big
Pharma manufacturing approach.
Vaccinomics and Directed
Vaccine Development
Our laboratory has advocated for a new
approach to vaccine discovery character-
ized as a ‘‘discover – validate – character-
ize – deploy’’ paradigm based on the
foundations of vaccinomics and personal-
ized vaccinology [2–4]. This approach
moves away from a focus on the smaller
details of immune function and advocates
pursuing an understanding of the immune
system as a whole in order to improve and
expand upon empirical vaccine science.
Furthermore, the approach is personalized
in that it emphasizes a tiered risk and
vaccination approach for new vaccines,
multiple avenues of vaccine administration
that take advantage of new findings (e.g.,
in mucosal immunology allowing for oral,
transcutaneous, depot, and mucosal deliv-
ery), multiple highly specific vaccine adju-
vants, directed vaccine development using
systems biology and computational ap-
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demic partnerships in the development of
new vaccine candidates. An initial aspect
of this new approach is the concept of
reverse vaccinology, which uses sophisti-
cated computer analysis of genomic data
to characterize pathogen antigens and
eliminate those with human homology.
This is followed by careful screening of the
remaining antigens for immunogenicity
and eventual use in new vaccine products
[5,6]. For example, reverse immunology
was used to create a recombinant protein
containing nine different Th epitopes that
has been used to enhance the hemophilus
influenza type b oligosaccharide vaccine
[7]. A large number of reverse immunol-
ogy studies have focused on the charac-
terization of T cell responses to vaccinia
virus and have identified hundreds of CD4
and CD8 T cell epitopes. Other studies
have carefully examined the vaccinia
transciptome. [8]. Vaccinomics seeks to
better and more fully integrate these
findings, correlating humoral and cellular
immune measures with transcriptomic,
genomic, and proteomic data to gain a
greater understanding of viral immunity.
One such integrated study has uncovered
complex interactions between CD4, CD8,
and humoral responses to vaccinia virus
[9].
Figure 1 outlines some of the important
features that might be employed by a
vaccinomics approach. It should be noted
that not all of these features may be
needed for a given vaccine, and those
features that are needed may be priori-
tized differently depending on the unique
constraints imposed by the disease, vac-
cine product, and/or population to be
protected. For example, cancer vaccines
have benefited greatly from advanced
bioinformatics, reverse immunology, and
epitope discovery to develop very person-
alized products. On the other hand, new
vaccines against leishmaniasis or Japanese
encephalitis for use in developing coun-
tries where distribution and inoculation
are handled by public/private organiza-
tions with access to at-risk populations and
familiarity with the local culture and
society may require the development of a
stable product not requiring a cold chain
and transdermal application such that
advanced training is not required for
administration.
The need for and importance of new
advances in vaccinology such as those
above may not be apparent to all. Above
and beyond the obvious value in decreas-
ing (or eliminating in the case of smallpox,
and hopefully soon polio and measles)
morbidity and mortality due to infectious
diseases, economic benefits accrue to
healthy populations, national security
may be enhanced, bioweapons develop-
ment countered, and new insights into
vaccine immunology generalized into oth-
er fields. As a result of these compelling
arguments for vaccines, we deliver a series
of vaccines to every human being on
earth, multiple times over a lifetime. The
importance of this is that there is nothing
comparable in medicine that so touches every single
human being. Indeed, this public health
approach toward vaccine use has contrib-
uted to a doubling of the lifespan in the
US over the last century by the control of
infectious diseases, and the supportive role
played by vaccines. But, as mentioned, it
has been a one-size-fits-all approach. In
the 21st century we may now ask, is such
an approach, for our time and age,
informed by science?
A variety of factors impact the heteroge-
neity and inter-individual variations in
vaccine-induced immune responses. These
include factors such as gender [10], age
[11], ethnicity [12], vaccine dose [13],
vaccine storage/cold chain [14], immune
system function/integrity [15], size (body
mass index [BMI]) [16], smoking [17], and
others. Logically, genetics play an impor-
tant—and defining—role in vaccine re-
sponse. We increasingly understand the role
of genetic causes of heterogeneity in treat-
ment effects with drugs, but similar work in
the field of vaccinology has lagged. One
investigator has observed, ‘‘Just as pharma-
cogenetics has suggested ways of designing
drugs to minimize population variability,
understanding mechanisms of immunogenetic
variationmaylead tonewvaccinesdesigned
to minimize immunogenetically based fail-
ure’’ [18]. This naturally leads to such
questions as, ‘‘why do immune responses to
biologics/vaccines vary among healthy
individuals? ‘‘And what explains this het-
erogeneity?’’ ‘‘Could the answers to these
questions be leveraged in reverse engineer-
ing new vaccine candidates?’’
The Immune Response Network
Theory
While we readily accept that genetic
variation in TCR genes, antibody genes,
Figure 1. New approach to vaccine discovery and development. Figure 1 illustrates the
differences between the one-size-fits-all approach of empiric vaccine development with a more
directed and personal approach that relies upon vaccinomics and high-dimensional ‘‘omics’’
technologies. By analogy, empiric vaccine development represents the undifferentiated light
entering the prism from the left. Individual aspects of directed vaccine development can be seen
when viewed through the prism of vaccinomics. Several examples of these components are
illustrated in the rainbow on the right side of the figure. These aspects may or may not be
appropriate for all vaccines and are used here to illustrate the wide range of possibilities that a
‘‘discover – validate – characterize – deploy’’ approach allows one to independently investigate,
optimize, and fully utilize. Below the vaccinomics prism are listed some examples (by no means
complete or definitive) representing a range of potential components that can be assembled into
a comprehensive, systems-level examination of infection/vaccination of a given pathogen. Please
refer to the text for examples of how different components might be used in the development of
specific vaccines.
doi:10.1371/journal.ppat.1002344.g001
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differential ability of the host to respond
to pathogens, these are not the only genes
that impact vaccine immunity. Host ge-
netic influences on inter-individual vari-
ability can also occur as a result of
polymorphisms in genes involved in the
generation of the immune response, in-
cluding viral receptors, Toll-like and other
pattern recognition receptors, signaling
molecules, cytokine and cytokine receptor
genes, Gm/Km genes, perforin and gran-
zymes, and death receptors, as well as
many others. In recognizing this, our
laboratory developed the ‘‘Immune Re-
sponse Network Theory,’’ which states
that the response to a vaccine is ‘‘the
cumulative result of interactions driven by
a host of genes and their interactions, and
is theoretically predictable’’ [19,20]. This
theory is different than Jerne’s idiotype
network theory stating that the antigen
recognition site of one antibody can in
turn serve as an antigen stimulating the
production of anti-idiotype antibodies, and
that these networks of antibodies/anti-
idiotypic antibodies serve to positively and
negatively regulate immune function [21].
‘‘The basic genetic elements of the im-
mune response network includes genes
activating/suppressing immune responses,
the dominance profile of a given gene or
polymorphism, epigenetic modifications of
genes, the influence of signaling genes,
innate response genes, gene-gene interac-
tions, and genes for other host response
factors’’ [2]. Understanding the complex
interplay of these networks and pathways
as a coherent system allows one to build
predictive models, anticipate possible side
effects, and observe synergistic outcomes
that cannot be foreseen with narrowly
focused studies concentrating on single
genes or proteins or even single cell types.
Understanding the key initial events in the
immune response to pathogen infection
allows us to identify viral ligands respon-
sible for cell binding and entry, innate
receptors responsible for pathogen detec-
tion, innate pathways mediating protective
responses specific for a given pathogen,
host pathways usurped by viral machinery,
and pathogen epitopes targeted by T and
B cells, and the interplay between T helper
lymphocytes and B cells or cytotoxic T
cells necessary for optimal humoral and
cell-mediated responses. In turn, this
information allows for the identification
of adjuvants stimulating the appropriate
innate receptors and antiviral pathways,
attenuation strategies for the pathogen of
interest, the appropriate selection of viral
epitopes for subunit vaccines, vaccine
products that omit the viral proteins
responsible for pathogen-induced damage
and suppress the host pathways responsi-
ble for immunopathology, the effects that
different routes of administration have on
the immune response, and the appropriate
dose/route/timing of immunizations to
properly elicit strong immune memory.
As we have noted, the mechanisms for
differential gene-based effects can include
‘‘differential binding, processing, and
expression/presentation of antigenic pep-
tides, a differential range of presented
peptides (genetic restriction), altered se-
cretion patterns (cytokines), altered tran-
scription of important genes (signaling
molecules) and gene products, altered
binding of virus/antigens by membrane-
based receptors (TLR, other), differential
receptor function, expression, affinities,
epigenetics, and of course, others’’ [22].
Further, our laboratory developed the
term ‘‘vaccinomics’’ to encompass the
integration of a systems biology approach
with immunogenetics, immunogenomics,
immune profiling, and functional SNP
studies in order to understand and
predict vaccine-induced immune re-
sponses. Using these concepts we have
predicted ‘‘a new golden era of person-
alized Predictive Vaccinology’’ whereby we
abandon a ‘‘one size and dose fits all
vaccine approach,’’ predict whether to
give a vaccine based on likelihood of
response (and perhaps need), predict the
likelihood of a significant adverse event
to a vaccine, predict the number of doses
likely to be needed to induce a response
to a vaccine (HBV, HPV, measles
examples), and design/develop new vac-
cines at the individual, gender-specific,
race-specific, or sub-population levels for
groups with identifiable and specific
genetic restrictions [3,4,23].
Genetic Control of Measle
Vaccine Response
As examples, we have focused our work
in vaccinomics on the study of measles,
rubella, smallpox, and influenza vaccines.
In order to understand the role of genetic
(host) variation in inter-individual vac-
cine-specific immune responses, we began
by performing twin studies (n =1 0 0
twins) to separate environmental and
genetic influences, to determine the influ-
ence of genetic factors relating to vari-
ability in immune response, to determine
the proportion of variation attributable to
specific genes, and to determine herita-
bility (the ratio of genetic variance to total
variance) [24]. In this study we deter-
mined that the heritability of measles
vaccine was 89% (p , 0.0001) [25]. We
next studied a cohort of healthy school-
children, all immunized with one dose of
MMR-II (medical record documentation),
with no circulating measles in the com-
munity since 1980 (the earliest year of
birth) [26,27]. The results are noted in
Figure 2, which demonstrates the diversi-
ty of inter-individual antibody response to
vaccine among otherwise healthy school-
children.
Figure 2. Distribution of measles vaccine–induced antibody levels. This graph represents
the distribution of antibody levels determined by an EIA assay on healthy grade-school children
immunized with a single dose of MMR-II vaccine. The inter-individual variation in antibody levels
among this healthy cohort illustrates the importance of determining the mechanisms for
heterogeneity in vaccine response.
doi:10.1371/journal.ppat.1002344.g002
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vaccine non-responders, we re-immu-
nized, and repeated antibody testing $ 6
weeks later. One hundred and six children
(81.5%) became seropositive, and 24
(18.5%) remained seronegative [28]. We
then re-examined our candidate gene
associations in individuals who had re-
ceived 2 doses of measles vaccine, and our
previously detectable class I and II HLA
effects were no longer detectable except
for B*4403 [22]—a similar finding in
studies of hepatitis B vaccine non-respond-
ers. Similarly, two doses of measles vaccine
appeared to overcome HLA homozygosity
associations with lower measles-specific
antibody and cytokine levels detected
following one dose of MMR vaccine
[29,30]. These findings illustrate that there
is HLA-restricted recognition of measles
virus epitopes with detectable impacts on
immunity, and that through an as yet
unclear mechanism, additional doses of
vaccine may help to overcome this genetic
restriction, including non-responsiveness
to measles vaccine.
Our population-based MMR vaccine
studies also determined that host gene
polymorphisms are associated with measur-
able inter-individual variations in measles
vaccine–induced immunity. Examples of
such gene SNPs include HLA, measles virus
binding CD46 and SLAM receptors, cyto-
kine and vitamin receptors, as well as innate
antiviral effector genes, including Toll-like
receptors (TLRs) and their signaling genes,
which play a significant role in contributing
tovariationsintheimmunity to measles due
to genetic polymorphisms [31–34]. The
adaptive immune response after measles
vaccination is influenced in part by HLA
gene polymorphisms. In fact, the occur-
rence or lack of specific HLA alleles and
haplotypes (or supertypes) may significantly
influence both humoral and cellular im-
mune responses to a vaccine. Furthermore,
our studies have demonstrated that genetic
polymorphisms in measles virus receptor
genes, pattern recognition receptor genes,
genes controlling innate antiviral responses,
and cytokines and cytokine receptor genes
are associated with variations in measles
vaccine–induced immune outcomes.
Associations with Measles-Specific
Humoral Immunity
We found several HLA alleles (B*3503,
DRB1*0701, and DQA1*0201) and hap-
lotypes (A*29-C*16-B*44 and DRB1*15/
15-DQB1*06-DPB1*03) with associations
with measles-specific neutralizing antibody
levels in two independent population-
based studies. Individual genetic variants
in the CD46 (rs11118580 and rs2724384)
and SLAM (rs164288) genes that appear
to modulate antibody responses to measles
vaccine were also identified [33]. In-
creased carriage of major allele variants
for coding SNPs in the TLR2 (rs3804100)
and TLR4 (rs5030710) genes were associ-
ated with a dose-related increase and a
dose-related decrease in measles antibody
levels, respectively [34]. Recently, we also
replicated a previously discovered associ-
ation of a functional IL12B genetic variant
rs3212227 with inter-individual variations
in measles-specific antibody levels [35].
Genetic variants within the RIG-I gene,
including a coding polymorphism (rs320
5166), were associated as single-SNPs and
in haplotype-level analysis, with measles
antibody variations [36].
Associations with Measles-Specific
Cellular Immunity
In a separate study we successfully
replicatedassociationswithtwooftheabove
mentioned measles virus receptor SNPs
(CD46 rs2724384 and SLAM rs164288)
and variations in measles antibody and
IFN-c Elispot responses, respectively [37].
A replicated CD46 polymorphism (rs272
4384) also demonstrated associations with
measles-specific IL-6 (p = 0.02), IFN-a
(p = 0.007), and TNF-a (p =0 . 0 0 0 7 )
responses. Two previously reported pro-
moter IL10 and IL2 SNPs (rs1800890 and
rs2069762) demonstrated associations with
measles-specific cellular response (p , 0.03)
[38]. A different polymorphism (rs112
65452) in the SLAM gene previously
associated with measles antibody levels
(p = 0.04)exhibited asignificantassociation
with measles-specific IL-10 production (p =
0.0008) [37]. Understanding the functional
or mechanistic consequences of genetic
variations such as those above on im-
mune-response variations could assist in
directing new vaccine design, and allows us
to generate and test new hypotheses
applicable to developing new measles
vaccine candidates.
Additional Examples of
Directed Vaccine Development
Taking these concepts further, hepatitis
B vaccine serves as a useful example. Both
HLA polymorphisms and cytokine SNPs
have been found to be associated with
hepatitis B vaccine non-response [39]. This
information could be utilized by developing
a candidate vaccine that included both
cytokine adjuvants to overcome genetic
restriction, and a peptide ‘‘cocktail’’ that
could circumvent known immunogenetic
restrictions, and investigators have begun
such development [40,41]. Similarly, we
have previously reported a SNP in the
SLAM receptor gene associated with a 4-
fold decrease in measles antibody levels
[33]. While mechanistic studies are ongo-
ing, it is logical that this SNP may interfere
with the ability of the measles vaccine virus
to bind to its receptor, and thereby perturb
the development of a protective immune
response. One could imagine a candidate
vaccine virus designed to allow binding
regardless of the presence or absence of
such a receptor polymorphism. Such a
vaccinomics approach could result in a
candidate vaccine that leads to protective
immune responses regardless of the pres-
ence of such a polymorphism. As a further
example, such an approach led to the
identification of the CCR5 deletion muta-
tion in the coding region of the CCR5 HIV
receptor. This information can be utilized
in the development of novel therapeutic
drugs and vaccines [42]. For example, a
subunit vaccine containing the CCR5
binding determinants of gp120 could be
created to facilitate the formation of viral
neutralizing antibody responses. In addi-
tion, adjuvants such as CpG or MPL-A
could differentially activate TLRs to cir-
cumvent restrictions in other receptors
[43].
Other limitations in the development of
new vaccines for measles and other infec-
tious pathogens include a lack of under-
standing of molecular mechanisms of
vaccine-induced adaptive immunity. While
we understand that viral peptides are
processed and presented in the context of
class I and II HLA molecules, this has
generally not informed the specific design
of new vaccine candidates. Our laboratory
has used this information to successfully
identify 13 novel naturally processed class
II HLA-DRB1*0301 measles virus peptides
[44,45]. The development of a high
performance mass spectrometry analytic
approach also allowed us to identify 116
naturally processed and presented class I
(A*0201, B*1501 and C*03) peptides
derived from vaccinia virus [46,47]. Re-
cently, we also isolated 17 naturally pro-
cessed avian influenza H5N1 peptides from
theclass I A*0201 peptidebindinggrove(P.
Tosh, I. Ovsyannikova, G. Poland, unpub-
lished data). Data on specific immunogenic
peptides (and adjuvants) such as these
become important in the design of future
vaccines to combat infectious diseases,
including measles, influenza, smallpox,
and other pathogens [48].
Conclusion
Our laboratory has used the live,
attenuated measles, mumps, rubella, and
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work and development of the vaccinomics
approach. After two decades of work with
measles vaccine virus we have determined
that:
N Almost 90% of measles vaccine re-
sponse heterogeneity is explainable
genetically
N Polymorphisms of specific immune
response genes significantly influence
measles vaccine–induced immunity
N Vaccine-induced immune responses
can be profiled (and in the near future
predicted)
N Naturally processed and presented
immunogenic peptides can be identi-
fied and sequenced, and represent a
novel method of vaccine candidate
discovery
The next step in the development of
vaccinomics is to understand immune
‘‘signature profiles’’ from a systems biology
perspective in order to develop vaccine
response ‘‘markers’’ in support of person-
alized vaccinology, and to inform new
vaccine development. An excellent exam-
ple of this concept is the identification of a
gene signature including C1QB and EI-
F2AK4, which correlated with and pre-
dicted CD8+ T cell responses to the yellow
fever vaccine with a high degree of
accuracy [49]. The authors also identified
a separate predictive signature of neutral-
izing antibody response that included the B
cell growth factor TNFRS17. Yet another
example of predictive immune profiling
has been demonstrated for influenza vac-
cination. The expression levels of CAM-
KIV (a calmodulin-dependent protein
kinase involved in neural functions as well
as stem cell maintenance and T cell
development) at day 3 following vaccina-
tion with TIV is inversely correlated with
antibody titers at the peak of the immune
response [50]. The development of these
predictive signatures provides significant
insights into the generation of vaccine-
induced immune responses, and may serve
as useful biomarkers for the testing of novel
vaccine candidates. The knowledge gained
from these immune-profiling studies may
indicate appropriate adjuvants or routes of
administration that can be coupled with
mass-spectrometry approaches to isolating
and identifying highly immunogenic viral
peptides, allow for peptide-based vaccine
development (an area of vaccine research
that currently suffers from poor immuno-
genicity), and allow us to anticipate novel,
directed development (rather than an
empiric approach) of a plethora of new
candidate vaccines informed by genotype:-
phenotype associations, the role of epige-
netics and complementarity, and other
future advances.
We believe that the future of vaccine
development, utilizing the tools of vacci-
nomics and predictive vaccinology, is such
that the science will move us to abandon a
‘‘one size and dose fits all empiric vaccine
approach,’’ predict vaccine response and
the possibility of a significant adverse
response to a vaccine, predict the number
of doses likely to be needed to induce a
response to a vaccine, and direct us toward
a science-based directed design/develop
paradigm for novel vaccine candidates. In
turn, abandoning the empiric approach of
vaccine development, and moving toward
a new paradigm of ‘‘discover – validate –
characterize – deploy’’ is likely to hold
promise in the development of vaccine
candidates for hyper-variable pathogens,
and overcome the current one-size-fits-all
approach that leads to substantial inter-
individual vaccine responses, vaccine non-
response, increased costs, and substantial
barriers to the development of novel
vaccine candidates.
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